DOM-URSODIOL C TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
23-04-2013
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
URSODIOL
から入手可能:
DOMINION PHARMACAL
ATCコード:
A05AA02
INN（国際名）:
URSODEOXYCHOLIC ACID
投薬量:
250MG
医薬品形態:
TABLET
構図:
URSODIOL 250MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
治療領域:
CHOLELITHOLYTIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0122789001; AHFS:
認証ステータス:
APPROVED
承認日:
2006-08-10
製品の特徴
PRODUCT MONOGRAPH
PR
DOM-URSODIOL C
Ursodiol Tablets USP
250 mg & 500 mg
CHOLESTATIC LIVER DISEASES
DOMINION PHARMACAL
DATE OF REVISION:
6111 Royalmount Avenue, Suite 100
April 23, 2013
Montreal, Quebec H4P 2T2
CONTROL NUMBER: 163339
_ _
_Dom-URSODIOL C Product Monograph _
_Page 2 of 29_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS..........................................................................................................
5
DRUG INTERACTIONS
........................................................................................................
10
DOSAGE AND ADMINISTRATION
....................................................................................
11
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 11
STORAGE AND STABILITY
................................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
.............................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
.....................................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................
14
CLINICAL TRIALS
.....................................................................................................
完全なドキュメントを読む
